Literature DB >> 3344809

Remnant kidney hypermetabolism and progression of chronic renal failure.

D C Harris1, L Chan, R W Schrier.   

Abstract

To investigate the mechanisms whereby verapamil and dietary phosphate restriction slow progression of nephron loss after renal ablation, the effects of these maneuvers on inulin clearance (CIn), net sodium reabsorption (TNa+), oxygen consumption (QO2), and net glucose production (GP) were examined in isolated perfused normal and remnant kidneys. Preliminary studies characterized the isolated perfused remnant kidney perfusion. Adaptation to renal ablation was greater for QO2 (102% of normal), GP (138%), and kidney weight (79%) than CIn (51%) or TNa+ (40%). Verapamil (50 microM) lowered QO2 in remnant kidneys (1.64 +/- 0.24 vs. control 2.86 +/- 0.16 mumol.min-1.g-1, P less than 0.005), as did phosphate restriction (1.81 +/- 0.22 vs. control 3.05 +/- 0.40 mumol.min-1.g-1, P less than 0.05). These effects could not be accounted for by changes in CIn, TNa+, or GP and were not observed in normal kidneys. In summary 1) remnant kidneys are hypermetabolic compared with normal kidneys when assessed by QO2 and GP; 2) verapamil and phosphate restriction diminish the enhanced metabolic activity of remnant kidneys, an effect that is independent of TNa+; and thus 3) verapamil and phosphate restriction may slow progression of renal disease, at least in part by reducing renal metabolic demands.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344809     DOI: 10.1152/ajprenal.1988.254.2.F267

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

Review 1.  Reactive oxygen molecules, oxidant injury and renal disease.

Authors:  S P Andreoli
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

Review 2.  Renal fibrosis: Primacy of the proximal tubule.

Authors:  Leslie S Gewin
Journal:  Matrix Biol       Date:  2018-02-06       Impact factor: 11.583

3.  Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway.

Authors:  Jianchun Chen; Jian-Kang Chen; Raymond C Harris
Journal:  Mol Cell Biol       Date:  2012-01-03       Impact factor: 4.272

4.  EGF receptor deletion in podocytes attenuates diabetic nephropathy.

Authors:  Jianchun Chen; Jian-Kang Chen; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2014-09-03       Impact factor: 10.121

5.  Hypoxia-inducible factor-1α activation improves renal oxygenation and mitochondrial function in early chronic kidney disease.

Authors:  Joanna L Thomas; Hai Pham; Ying Li; Elanore Hall; Guy A Perkins; Sameh S Ali; Hemal H Patel; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-22

6.  Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients.

Authors:  R Bitar; O Flores; M Reverte; J M López-Novoa; J F Macías
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

7.  Interactions between HIF-1α and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease.

Authors:  Hui Li; Joseph Satriano; Joanna L Thomas; Satoshi Miyamoto; Kumar Sharma; Núria M Pastor-Soler; Kenneth R Hallows; Prabhleen Singh
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-01

8.  Regulation of oxygen utilization by angiotensin II in chronic kidney disease.

Authors:  Aihua Deng; Tong Tang; Prabhleen Singh; Chen Wang; Joe Satriano; Scott C Thomson; Roland C Blantz
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

9.  Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation.

Authors:  Sunfa Cheng; David H Lovett
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

Review 10.  Recent advances in renal hypoxia: insights from bench experiments and computer simulations.

Authors:  Anita T Layton
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.